

Rating: HOLD | CMP: Rs6,407 | TP: Rs6,000

January 20, 2026

**Q3FY26 Result Update**

☑ Change in Estimates | ☑ Target | ■ Reco

**Change in Estimates**

Rating	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	HOLD		HOLD	
Target Price	6,000		5,830	
Sales (Rs bn)	468	529	465	521
% Chng.	0.8	1.6		
EBITDA (Rs bn)	85	98	84	95
% Chng.	1.8	2.4		
EPS (Rs.)	208.5	239.4	204.7	233.9
% Chng.	1.8	2.4		

**Key Financials - Consolidated**

Y/e Mar	FY25	FY26E	FY27E	FY28E
Sales (Rs. bn)	380	421	468	529
EBITDA (Rs. bn)	65	75	85	98
Margin (%)	17.1	17.9	18.2	18.5
PAT (Rs. bn)	46	55	62	71
EPS (Rs.)	155.4	184.9	208.5	239.4
Gr. (%)	0.3	18.9	12.8	14.8
DPS (Rs.)	65.1	77.5	87.4	100.4
Yield (%)	1.0	1.2	1.4	1.6
RoE (%)	21.5	22.7	22.7	22.8
RoCE (%)	19.1	19.7	19.8	20.0
EV/Sales (x)	4.7	4.2	3.7	3.2
EV/EBITDA (x)	27.5	23.5	20.4	17.4
PE (x)	41.2	34.7	30.7	26.8
P/BV (x)	8.4	7.5	6.5	5.7

**Key Data**

	LTIM.BO   LTIM IN
52-W High / Low	Rs.6,430 / Rs.3,802
Sensex / Nifty	83,246 / 25,586
Market Cap	Rs.1,900bn/ \$ 20,894m
Shares Outstanding	296m
3M Avg. Daily Value	Rs.1694.81m

**Shareholding Pattern (%)**

Promoter's	68.57
Foreign	6.62
Domestic Institution	16.20
Public & Others	8.61
Promoter Pledge (Rs bn)	-

**Stock Performance (%)**

	1M	6M	12M
Absolute	3.4	25.0	8.8
Relative	5.5	22.8	0.1

Pritesh Thakkar

priteshthakkar@plindia.com | 91-22-66322533

Sujay Chavan

sujaychavan@plindia.com | 91-22-66322536

**Top clients transition nears completion, growth uptick in sight**
**Quick Pointers:**

- Growth momentum continues with steady operating margin
- Deal wins remains steady at USD 1.69 bn compared to USD 1.59 bn in Q2

**The revenue growth (+2.4% QoQ CC) was above our estimates (2.0% QoQ CC), aided by ramp up of large deals and pass-throughs. Beyond selective pockets the growth was muted, especially BFSI and CMT verticals. The deal signing activities remain strong in these verticals, it will take few more quarters to achieve the normalized revenue run-rate for top marquee accounts. Although top 5/10 accounts de-grew 2.9%/1.1% TTM (vs decline of 5.2%/2.2% LQ), the pace of deceleration has reduced sequentially, implies recovery post productivity benefits. The management was confident of executing even better and aspired to achieve near to double-digit YoY growth in Q4. The company's participation in vendor consolidation deals along with continued momentum in NN wins translate to a better growth visibility. The recent India-led NN deal (CBDT) would itself contribute ~80-90bps to the topline in FY27. On margins, it was able to sustain margins at a Q2 high base despite having pass-throughs, aided by internal margin program (fit-for-future) and INR depreciation supporting margins in Q3. We are keeping our margin estimates largely unchanged as the wage hike impact would keep margins under pressure. We are baking CC revenue growth of 5.4%/8.9%/9.5% YoY in FY26E/FY27E/FY28E, while keeping our margins at 15.3%/15.6%/15.9%. With that our EPS sees an upgrade of ~2% each in FY27E/FY28E. We assign 25x PE to FY28E EPS for a TP of 6,000, full valuations. Retain HOLD.**

**Revenue:** LTIM delivered steady revenue growth of 2.4% QoQ in CC & reported terms, ahead of our estimate of ~2% QoQ CC. Growth was driven by Healthcare and Manufacturing, which grew 9.9% and 9.4% QoQ, respectively, in USD terms, while the Consumer segment grew 1.2% QoQ. In contrast, the two largest segments were weak, with BFSI declining 0.7% QoQ and CMT remaining flat. Geographically, growth was led by the RoW (+14.1% QoQ), while Europe (+3.4% QoQ) and North America (+0.4% QoQ) posted modest growth.

**Margin:** EBIT margins improved marginally, with adjusted EBIT margin rising 20 bps QoQ to 16.1%. A ~90 bps QoQ decline in gross margin, driven by lower utilization and seasonal factors, was offset by lower SG&A expenses and favorable currency movement, while lower depreciation contributed ~20 bps to margin expansion. Reported PAT was impacted by a one-time ₹5.9 bn provision related to changes in the labour code.

**Deal Wins:** Deal wins remained steady, with TCV of USD 1.69 bn in Q3, compared to USD 1.59 bn in the previous quarter. During the quarter, LTIM secured multiple large deals, including a USD 155 mn, five-year contract with a US-based insurance company, underscoring continued traction in large, multi-year engagements.

**Valuations and outlook:** We are factoring in USD revenue and earnings CAGR of 9.2% and 13.8%, respectively. The stock is currently trading at 27x of its FY28E earnings, and we assign a target PE of 25x FY28E earnings to arrive at a target price of Rs. 6,000. We maintain our "HOLD" rating.

### Slight beat in revenue while operating margin remains steady

- Revenue stood at USD 1.21 bn, up 2.4% QoQ in CC & reported terms, above our est. of +2% QoQ CC
- **Vertical wise in reported terms the growth was led by Healthcare which grew by 9.9% QoQ on back of ramp up of large deal & Manufacturing which grew by 9.4% QoQ (likely due to higher passthrough). Consumer grew by 1.2% QoQ while BFSI declined by 0.7% QoQ**
- Geography wise, RoW & Europe grew by 14.1% & 3.4% QoQ respectively while North America grew by 0.4%
- Adj. EBIT margin came at 16.1%, up 30 bps % QoQ, slightly above of our & consensus est. of 15.9% due to lower depreciation & amortization expenses while gross margin decline was offset by lower SG&A expenses
- **Net headcount grew by 1.5k in quarter while Utilization declined by 120 bp QoQ to 86.9%. LTM Attrition declined by 40 bps QoQ to 13.8%**
- **Order inflows were steady came at USD 1.69 bn, up 6.3% QoQ & 0.6% YoY, with BTB of 1.4x**
- PAT came in at INR 14 bn, up 0.7% QoQ & 27.9% YoY

### Conference Call Highlights

- Management noted that top five client revenues continue to remain under pressure due to ongoing AI-led productivity initiatives at large accounts, rather than any loss of wallet share. Four of the five clients have largely completed their transition, with the remaining account expected to bottom out in Q4, easing the near-term growth headwinds.
- BFSI performance remained weak in Q3, with revenues declining 0.7% QoQ, primarily due to AI-led productivity initiatives at a large client, rather than demand softness or wallet-share loss. Management indicated that the drag is largely confined to one top account, which is expected to bottom out in Q4. Excluding this client, the broader BFSI portfolio continues to grow faster than the company average, supported by strong positioning as a prime vendor at multiple large global banks. Management expects BFSI growth momentum to normalize from Q4 and improve further into FY27.
- The CMT segment reported flat QoQ performance in Q3, reflecting a muted demand environment and ongoing client-side productivity initiatives, particularly within large technology accounts. Management indicated that revenue trends have stabilized, with productivity reset largely behind. Going forward, growth is expected to improve gradually, supported by deal ramp-ups, AI-led transformation programs.

- Management noted that deal renewals are becoming increasingly strategic & acting as inflection points for vendor consolidation and wallet-share gains rather than simple extensions. They further noted that this provides opportunities for expanding scope of work and expand its opportunity per client.
- Management aspires to deliver industry-leading growth, targeting a strong Q4 exit with revenue growth approaching double-digit YoY levels. While the demand environment remains cautious, growth is supported by cost optimization, vendor consolidation, and AI-led transformation, with momentum expected to carry into FY27.
- Management reiterated its focus on sustaining and gradually expanding EBIT margins through productivity initiatives under the Fit for Future / New Horizon programs, despite near-term headwinds.
- Segment margin performance was mixed in Q3. BFSI margins improved sequentially, driven by pyramid optimization, better rate realization, fresher deployment, and forex benefits under the Fit for Future program. In contrast, Hi-Tech (CMT) margins remained under pressure, reflecting earlier client-side productivity initiatives and revenue softness.
- Wage hikes are to be implemented in Q4, covering around 50% of the workforce and to be phased over multiple quarters, with an estimated margin headwind of ~100 bps per quarter, partly mitigated through operational levers and efficiency gains.

**Exhibit 1: 3QFY26 Results: Slight beat in revenue while operating margin remains stable**

Consolidated (INR b)	3QFY26	3QFY26E	% Var.	2QFY26	QoQ gr.	3QFY25	YoY gr.	9MFY26	9MFY25	YoY gr.
IT Services Revenue (USD m)	1,208	1,202	0.5	1,180	2.4	1,139	6.1	3,541	3,362	5.4
Overall Revenue (INR b)	108	108	-0.1	104	3.7	97	11.6	310	282	9.8
<b>Gross Profit</b>	<b>32</b>	<b>33</b>	<b>-4.0</b>	<b>32</b>	<b>0.7</b>	<b>28</b>	<b>14.0</b>	<b>92</b>	<b>85</b>	<b>8.5</b>
Gross Margin (%)	29.4	30.6	-120bps	30.3	-90bps	28.8	60bps	29.6	30.0	-40bps
SG&A and Other Costs	11.7	13.0	-9.8	12.2	-4.2	11.9	-1.7	36	36	1.1
% of Rev	10.8	12.0	-120bps	11.7	-90bps	12.3	-150bps	11.6	12.6	-100bps
<b>EBITDA</b>	<b>20</b>	<b>20</b>	<b>-0.3</b>	<b>19</b>	<b>3.8</b>	<b>16</b>	<b>25.7</b>	<b>56</b>	<b>49</b>	<b>14.0</b>
EBITDA Margin (%)	18.6	18.6	0bps	18.6	0bps	16.5	210bps	18.0	17.3	60bps
Depreciation	3	3	-8.9	3	-6	3	0.5	8	7	6.7
% of Rev	2.5	2.7	-20bps	2.7	-20bps	2.7	-30bps	2.5	2.6	-10bps
<b>EBIT</b>	<b>17</b>	<b>17</b>	<b>1.2</b>	<b>16</b>	<b>5.4</b>	<b>13</b>	<b>30.7</b>	<b>48</b>	<b>42</b>	<b>15.2</b>
EBIT Margin (%)	16.1	15.9	20bps	15.9	30bps	13.8	240bps	15.4	14.7	70bps
Other Income (net)	2	2	-36.5	2	-31.8	1	9.8	7	5	34.5
<b>PBT</b>	<b>19</b>	<b>20</b>	<b>-3.6</b>	<b>19</b>	<b>0.8</b>	<b>15</b>	<b>28.7</b>	<b>55</b>	<b>47</b>	<b>17.4</b>
Tax	5	5	-0.9	5	1.3	4	30.8	15	12	21.7
Effective tax rate (%)	26.6	25.9	70bps	26.5	10bps	26.2	40bps	26.8	25.9	90bps
<b>Adjusted PAT</b>	<b>14</b>	<b>15</b>	<b>-4.5</b>	<b>14</b>	<b>0.7</b>	<b>11</b>	<b>27.9</b>	<b>41</b>	<b>35</b>	<b>16.9</b>
Exceptional items	4	0	NA	0	NA	0	NA	4	0	NA
<b>Reported PAT</b>	<b>10</b>	<b>15</b>	<b>-34.1</b>	<b>14</b>	<b>-30.5</b>	<b>11</b>	<b>-11.7</b>	<b>36</b>	<b>35</b>	<b>4.5</b>
<b>Reported EPS (INR)</b>	<b>47</b>	<b>49</b>	<b>-3.8</b>	<b>47</b>	<b>0.0</b>	<b>37</b>	<b>29.0</b>	<b>137</b>	<b>117</b>	<b>16.8</b>

Source: Company, PL

**Exhibit 2: Regional growth (%)**

Geographies	Contribution to revenue (%)	QoQ gr. (%)
North America	72.8	0.4
Europe	14.8	3.1
RoW	12.4	14.4

Source: Company, PL

**Exhibit 3: Vertical Growth (%)**

Verticals	Contribution to revenue (%)	QoQ gr. (%)
BFSI	35.1	(0.7)
Manufacturing	20.8	9.2
CPG, Retail & Pharma	15.4	1.1
High-Tech, Media & Entertainment	22.2	0.1
Healthcare	6.5	10.9


Source: Company, PL

**Exhibit 4: Key Performance Indicator**

	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26	FY25*	FY26*
Revenue (QoQ CC %)	-1.3	2.6	2.3	1.8	-0.6	0.8	2.4	2.4	5.0	5.4
Margins (%)										
Gross Margin	29.8	30.3	30.8	28.8	27.9	29.1	30.3	29.4	29.4	29.4
EBIT Margin	14.7	15.0	15.5	13.8	13.8	14.3	15.9	16.1	14.5	15.3
Net Margin	12.4	12.4	13.3	11.2	11.5	12.7	13.5	13.0	12.1	13.0
Operating metrics										
Headcount	81.7	81.9	84.4	86.8	84.3	83.9	86.4	88.0	84.3	-
Attrition (%)	14.4	14.4	14.5	14.3	14.4	14.4	14.2	13.8	14.4	-
Utilization (excl. trainees)	86.9	88.3	87.7	85.4	85.8	88.1	88.1	86.9	85.8	-


Source: Company, PL, \* YoY CC

**Exhibit 5: Steady revenue growth in Q3**




Source: Company, PL

**Exhibit 6: EBIT margin (%) improved by 20 bps QoQ**




Source: Company, PL

**Exhibit 7: BFSI growth (QoQ %) impacted by top client**




Source: Company, PL

**Exhibit 8: North America (QoQ %) muted in Q3**




Source: Company, PL

**Exhibit 9: Utilization (Ex. Trainees %) declined from peak level**




Source: Company, PL

**Exhibit 10: Attrition (LTM %) declined by 40 bps QoQ**



Source: Company, PL

**Exhibit 11: Order Inflows (USD b) steady during the quarter**



Source: Company, PL

**Exhibit 12: Operating Metrics**

	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26
<b>Revenue by verticals (%)</b>												
BFSI	38.0	37.5	36.5	35.6	35.1	35.2	35.6	36.4	37.1	37.0	36.2	35.1
Manufacturing	17.5	17.3	17.9	20.3	18.6	18.5	18.1	19.3	19.9	19.6	19.5	20.8
CPG, retail & pharma	15.4	15.1	15.3	14.7	15.1	14.5	14.5	14.3	14.1	14.6	15.6	15.4
High tech, media & entertainment	23.0	23.7	23.8	22.9	24.3	25.6	25.4	23.7	23.4	23.2	22.7	22.2
Healthcare, Life, Public Science	6.1	6.4	6.5	6.5	6.9	6.2	6.4	6.3	5.5	5.6	6.0	6.5
<b>Revenue by geography (%)</b>												
North America	71.9	73.1	73.4	72.7	73.8	75.1	75.0	74.7	74.5	74.4	74.2	72.8
Europe	15.4	15.2	15.3	14.5	14.6	14.4	14.4	13.8	13.6	14.7	14.7	14.8
ROW	12.7	11.7	11.3	12.8	11.6	10.5	10.6	11.5	11.9	11.0	11.1	12.4
<b>Client metrics (% of revenues)</b>												
Top 5 client	25.4	26.7	26.8	27.5	28.3	28.8	28.4	27.9	27.7	27.3	25.3	24.0
Top 10 client	32.9	34.1	34.3	35.3	35.5	35.7	35.0	34.5	34.3	34.3	32.8	31.7
Top 20 client	44.0	44.9	45.2	45.9	45.9	46.2	45.8	45.5	44.8	44.5	43.5	43.3
Top 40 client	56.8	57.2	57.6	58.5	58.0	58.9	58.2	58.1	57.2	56.8	56.1	56.8
Non Top 20 clients	56.0	55.1	54.8	54.1	54.1	53.8	54.2	54.5	55.2	55.5	56.5	56.7
Number of active clients	728	723	737	739	738	748	742	742	741	741	749	746
New clients added in the period	31	19	30	23	30	27	22	23	26	17	23	26
<b>Million \$ clients</b>												
5 Million \$ clients	146	148	146	149	153	148	154	152	154	159	158	162
10 Million \$ clients	81	88	90	89	91	87	88	90	89	90	93	97
20 Million \$ clients	38	40	41	40	40	43	42	39	40	41	45	47
50 Million \$ clients	13	13	14	12	13	12	12	13	14	14	14	12
100 Million \$ clients	2	2	2	2	2	2	2	2	2	2	2	2
<b>Employee metrics (in k's)</b>												
Development	80.3	77.6	78.3	77.2	76.5	76.8	79.4	81.6	79.1	78.7	81.4	82.9
Sales and support	4.3	5.2	5.3	5.3	5.2	5.1	5.1	5.2	5.2	5.2	5.1	5.0
Total employees	84.5	82.7	83.5	82.5	81.7	81.9	84.4	86.8	84.3	83.9	86.4	88.0
<b>Efforts mix</b>												
Onsite	14.9	14.8	14.8	15.0	15.1	15.4	15.5	15.4	15.1	15.1	14.8	14.5
Offshore	85.1	85.2	85.2	85.0	84.9	84.6	84.5	84.6	84.9	84.9	85.2	85.5
<b>Utilization measures</b>												
Excluding trainees	81.7	84.8	86.6	87.4	86.9	88.3	87.7	85.4	85.8	88.1	88.1	86.9
<b>Attrition LTM (%)</b>	20.2	17.8	15.2	14.2	14.4	14.4	14.5	14.3	14.4	14.4	14.2	13.8

Source: Company, PL

## Financials

### Income Statement (Rs bn)

Y/e Mar	FY25	FY26E	FY27E	FY28E
<b>Net Revenues</b>	<b>380</b>	<b>421</b>	<b>468</b>	<b>529</b>
YoY gr. (%)	7.0	10.7	11.3	13.0
Employee Cost	268	297	328	369
<b>Gross Profit</b>	<b>112</b>	<b>124</b>	<b>140</b>	<b>160</b>
Margin (%)	29.4	29.4	30.0	30.3
Employee Cost	-	-	-	-
Other Expenses	-	-	-	-
<b>EBITDA</b>	<b>65</b>	<b>75</b>	<b>85</b>	<b>98</b>
YoY gr. (%)	1.7	15.9	13.1	14.8
Margin (%)	17.1	17.9	18.2	18.5
Depreciation and Amortization	10	11	12	14
<b>EBIT</b>	<b>55</b>	<b>64</b>	<b>73</b>	<b>84</b>
Margin (%)	14.5	15.3	15.6	15.9
Net Interest	-	-	-	-
Other Income	7	10	10	12
<b>Profit Before Tax</b>	<b>62</b>	<b>74</b>	<b>83</b>	<b>96</b>
Margin (%)	16.3	17.6	17.8	18.1
Total Tax	16	20	22	25
Effective tax rate (%)	25.9	26.6	25.9	25.9
<b>Profit after tax</b>	<b>46</b>	<b>54</b>	<b>62</b>	<b>71</b>
Minority interest	0	0	0	0
Share Profit from Associate	-	-	-	-
<b>Adjusted PAT</b>	<b>46</b>	<b>55</b>	<b>62</b>	<b>71</b>
YoY gr. (%)	0.3	18.9	12.8	14.8
Margin (%)	12.1	13.0	13.2	13.4
Extra Ord. Income / (Exp)	-	(4)	-	-
<b>Reported PAT</b>	<b>46</b>	<b>50</b>	<b>62</b>	<b>71</b>
YoY gr. (%)	0.3	9.6	22.4	14.8
Margin (%)	12.1	12.0	13.2	13.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	46	50	62	71
<b>Equity Shares O/s (bn)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>EPS (Rs)</b>	<b>155.4</b>	<b>184.9</b>	<b>208.5</b>	<b>239.4</b>

Source: Company Data, PL Research

### Balance Sheet Abstract (Rs bn)

Y/e Mar	FY25	FY26E	FY27E	FY28E
<b>Non-Current Assets</b>				
<b>Gross Block</b>	<b>79</b>	<b>88</b>	<b>97</b>	<b>106</b>
Tangibles	62	71	80	89
Intangibles	17	17	17	17
<b>Acc: Dep / Amortization</b>	<b>50</b>	<b>61</b>	<b>73</b>	<b>87</b>
Tangibles	37	47	59	73
Intangibles	14	14	14	14
<b>Net fixed assets</b>	<b>28</b>	<b>26</b>	<b>23</b>	<b>18</b>
Capital Work In Progress	-	-	-	-
Goodwill	12	12	12	12
Non-Current Investments	20	20	20	20
Net Deferred tax assets	5	6	6	7
Other Non-Current Assets	32	33	35	40
<b>Current Assets</b>				
Investments	89	109	129	149
Inventories	-	-	-	-
Trade receivables	77	86	96	109
Cash & Bank Balance	21	19	31	43
Other Current Assets	20	23	25	28
<b>Total Assets</b>	<b>306</b>	<b>337</b>	<b>380</b>	<b>429</b>
<b>Equity</b>				
Equity Share Capital	0	0	0	0
Other Equity	227	254	290	331
<b>Total Networth</b>	<b>227</b>	<b>254</b>	<b>290</b>	<b>331</b>
<b>Non-Current Liabilities</b>				
Long Term borrowings	-	-	-	-
Provisions	0	0	0	0
Other non current liabilities	19	19	19	19
<b>Current Liabilities</b>				
ST Debt / Current of LT Debt	-	-	-	-
Trade payables	15	17	19	21
Other current liabilities	44	46	51	56
<b>Total Equity &amp; Liabilities</b>	<b>306</b>	<b>336</b>	<b>380</b>	<b>429</b>

Source: Company Data, PL Research

**Cash Flow (Rs bn)**

Y/e Mar	FY25	FY26E	FY27E	FY28E
PBT	46	50	62	71
Add. Depreciation	10	11	12	14
Add. Interest	3	-	-	-
Less Financial Other Income	7	10	10	12
Add. Other	(8)	-	-	-
Op. profit before WC changes	51	61	74	85
Net Changes-WC	(5)	(11)	(7)	(13)
Direct tax	0	-	-	-
<b>Net cash from Op. activities</b>	<b>45</b>	<b>50</b>	<b>67</b>	<b>71</b>
Capital expenditures	(9)	(9)	(9)	(9)
Interest / Dividend Income	4	-	-	-
Others	(12)	(20)	(20)	(20)
<b>Net Cash from Inv. activities</b>	<b>(17)</b>	<b>(29)</b>	<b>(29)</b>	<b>(29)</b>
Issue of share cap. / premium	0	-	-	-
Debt changes	(2)	-	-	-
Dividend paid	(19)	(23)	(26)	(30)
Interest paid	-	-	-	-
Others	(4)	-	-	-
<b>Net cash from Fin. activities</b>	<b>(26)</b>	<b>(23)</b>	<b>(26)</b>	<b>(30)</b>
<b>Net change in cash</b>	<b>2</b>	<b>(2)</b>	<b>12</b>	<b>13</b>
Free Cash Flow	36	41	58	62

Source: Company Data, PL Research

**Key Financial Metrics**

Y/e Mar	FY25	FY26E	FY27E	FY28E	
<b>Per Share(Rs)</b>					
EPS		155.4	184.9	208.5	239.4
CEPS		188.9	221.3	249.6	285.9
BVPS		766.8	859.6	980.7	1,119.7
FCF		121.5	137.9	195.2	210.2
DPS		65.1	77.5	87.4	100.4
<b>Return Ratio(%)</b>					
RoCE		19.1	19.7	19.8	20.0
ROIC		16.5	17.2	17.1	17.3
RoE		21.5	22.7	22.7	22.8
<b>Balance Sheet</b>					
Net Debt : Equity (x)	(0.5)	(0.5)	(0.6)	(0.6)	
Net Working Capital (Days)	59	60	60	60	
<b>Valuation(x)</b>					
PER		41.2	34.7	30.7	26.8
P/B		8.4	7.5	6.5	5.7
P/CEPS		33.9	29.0	25.7	22.4
EV/EBITDA		27.5	23.5	20.4	17.4
EV/Sales		4.7	4.2	3.7	3.2
Dividend Yield (%)		1.0	1.2	1.4	1.6

Source: Company Data, PL Research

**Quarterly Financials (Rs bn)**

Y/e Mar	Q4FY25	Q1FY26	Q2FY26	Q3FY26
<b>Net Revenue</b>	<b>98</b>	<b>98</b>	<b>104</b>	<b>108</b>
YoY gr. (%)	9.9	7.6	10.2	11.6
Raw Material Expenses	70	70	72	76
Gross Profit	27	29	32	32
Margin (%)	27.9	29.1	30.3	29.4
<b>EBITDA</b>	<b>16</b>	<b>16</b>	<b>19</b>	<b>20</b>
YoY gr. (%)	3.9	2.7	13.6	25.7
Margin (%)	16.3	16.8	18.6	18.6
Depreciation / Depletion	3	2	3	3
<b>EBIT</b>	<b>13</b>	<b>14</b>	<b>16</b>	<b>17</b>
Margin (%)	13.8	14.3	15.9	16.1
Net Interest	-	-	-	-
Other Income	2	3	2	2
<b>Profit before Tax</b>	<b>15</b>	<b>17</b>	<b>19</b>	<b>19</b>
Margin (%)	15.7	17.5	18.1	17.6
Total Tax	4	5	5	5
Effective tax rate (%)	26.2	27.3	26.5	26.6
<b>Profit after Tax</b>	<b>11</b>	<b>13</b>	<b>14</b>	<b>14</b>
Minority interest	-	-	-	-
Share Profit from Associates	-	-	-	-
<b>Adjusted PAT</b>	<b>11</b>	<b>13</b>	<b>14</b>	<b>14</b>
YoY gr. (%)	2.5	10.4	12.0	29.1
Margin (%)	11.5	12.7	13.5	13.0
Extra Ord. Income / (Exp)	-	-	-	-
<b>Reported PAT</b>	<b>11</b>	<b>13</b>	<b>14</b>	<b>18</b>
YoY gr. (%)	2.5	10.4	12.0	68.8
Margin (%)	11.5	12.7	13.5	17.0
Other Comprehensive Income	-	-	-	-
<b>Total Comprehensive Income</b>	<b>11</b>	<b>13</b>	<b>14</b>	<b>18</b>
Avg. Shares O/s (bn)	-	-	-	-
<b>EPS (Rs)</b>	<b>38.1</b>	<b>42.3</b>	<b>47.3</b>	<b>47.3</b>

Source: Company Data, PL Research

**Key Operating Metrics**

Y/e Mar	FY25	FY26E	FY27E	FY28E
Revenue (USD mn)	4,493	4,774	5,205	5,692

Source: Company Data, PL Research

**Price Chart**



**Recommendation History**

No.	Date	Rating	TP (Rs.)	Share Price (Rs.)
1	02-Jan-26	Hold	5,830	6,112
2	17-Oct-25	Hold	5,470	5,623
3	04-Oct-25	Hold	5,380	5,120
4	18-Jul-25	Hold	5,340	5,195
5	01-Jul-25	Hold	5,060	5,312
6	24-Apr-25	Accumulate	4,980	4,537
7	03-Apr-25	BUY	5,790	4,500
8	27-Mar-25	BUY	5,790	4,620

**Analyst Coverage Universe**

Sr. No.	Company Name	Rating	TP (Rs)	Share Price (Rs)
1	Coforge	BUY	2,140	1,642
2	Cyient	Hold	1,070	1,109
3	HCL Technologies	BUY	1,910	1,667
4	Infosys	BUY	1,900	1,600
5	KPIT Technologies	BUY	1,380	1,168
6	L&T Technology Services	Hold	4,070	4,244
7	Latent View Analytics	BUY	630	454
8	LТИMindtree	Hold	5,830	6,112
9	Mphasis	BUY	3,450	2,820
10	Persistent Systems	BUY	7,060	6,283
11	Tata Consultancy Services	BUY	4,040	3,240
12	Tata Elxsi	Hold	5,500	5,793
13	Tata Technologies	Hold	660	651
14	Tech Mahindra	Accumulate	1,860	1,671
15	Wipro	Hold	260	267

**PL's Recommendation Nomenclature (Absolute Performance)**

<b>Buy</b>	: > 15%
<b>Accumulate</b>	: 5% to 15%
<b>Hold</b>	: +5% to -5%
<b>Reduce</b>	: -5% to -15%
<b>Sell</b>	: < -15%
<b>Not Rated (NR)</b>	: No specific call on the stock
<b>Under Review (UR)</b>	: Rating likely to change shortly

## **ANALYST CERTIFICATION**

### **(Indian Clients)**

We/I, Mr. Pritesh Thakkar- MBA Finance, Mr. Sujay Chavan- MMS-Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### **(US Clients)**

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

## **DISCLAIMER**

### **Indian Clients**

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd. which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at [www.plindia.com](http://www.plindia.com).

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipient's particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report. PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report. PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Pritesh Thakkar- MBA Finance, Mr. Sujay Chavan- MMS-Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

### **US Clients**

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

## **Prabhudas Lilladher Pvt. Ltd.**

3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018, India | Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

[www.plindia.com](http://www.plindia.com)